BIOSANTE PHARMACEUTICALS INC Form SC 13G/A February 14, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 1)

BIOSANTE PHARMACEUTICALS, INC. _____ -----(Name of Issuer) COMMON STOCK, \$0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 09065 V 10 4 _____ (CUSIP Number) JANUARY 10, 2002 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: / / Rule 13d-1(b) / / Rule 13d-1(c) /X/ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 7

CUSIP No. 09065 V 10 4

(1) Names of Reporting Personal I.R.S. Identification N	sons. Nos. of above persons (entities only).
	Ross Mangano
(2) Check the Appropriate F	
	Not Applicable
(3) SEC Use Only	
(4) Citizenship or Place of	f Organization
	United States of America
Number of Shares Beneficially Owned by Each Reporting Person With:	(5) Sole Voting Power 15,055,000 (see Item 4)
	(6) Shared Voting Power 0
	(7) Sole Dispositive Power 15,055,000 (see Item 4)
	(8) Shared Dispositive Power
(9) Aggregate Amount Benefi	icially Owned by Each Reporting Person
	15,055,000 (see Item 4)
	Amount in Row (9) Excludes Certain Shares (See
	Not Applicable
(11) Percent of Class Repres	sented by Amount in Row (9)
	22.1%
(12) Type of Reporting Person	on (See Instructions)
	IN
	Page 2 of 7
CUSIP No. 09065 V 10 4	
(1) Names of Reporting Pers	sons. Nos. of above persons (entities only).

JO & Co

2

(2) Check the Appropriate of a Group (See Instru	Box if a Member (a) / / uctions) (b) / /
	Not Applicable
(3) SEC Use Only	
(4) Citizenship or Place	of Organization
	Indiana Corporation
Number of Shares Beneficially Owned by Each Reporting Person With:	(5) Sole Voting Power 11,550,000 (see Item 4)
	(6) Shared Voting Power
	(7) Sole Dispositive Power 11,550,000 (see Item 4)
	(8) Shared Dispositive Power
(9) Aggregate Amount Bene:	ficially Owned by Each Reporting Person
	11,550,000 (see Item 4)
	e Amount in Row (9) Excludes Certain Shares (See / /
	Not Applicable
(11) Percent of Class Repre	esented by Amount in Row (9)
	17.2%
(12) Type of Reporting Pers	son (See Instructions)
	со
	Page 3 of 7
ITEM 1.	
(a) Name of Issuer	
The name of the	e issuer is BioSante Pharmaceuticals, Inc.
(b) Address of Issue:	r's Principal Executive Offices
	the principal executive offices of BioSante is 111 ard, Suite 280, Lincolnshire, Illinois 60069.

ITEM 2.

(a) Name of Person Filing

Ross Mangano and JO & Co.

(b) Address of Principal Business Office or, if none, Residence

The address of Mr. Mangano's and JO & Co's principal place of business is 112 West Jefferson Boulevard, Suite 613, South Bend, Indiana 46634.

(c) Citizenship

Mr. Mangano is a United States citizen and JO & Co is an Indiana corporation.

(d) Title of Class of Securities

The class of equity securities to which this Statement relates is the common stock, \$0.0001 par value per share, of BioSante Pharmaceuticals, Inc.

(e) CUSIP Number

The CUSIP number of the common stock is 09065 V 10 4.

- ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
 - (a) / Broker or dealer registered under section 15 of the Act (15 U.S.C. 780).
 - (b) / Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
 - (c) / Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
 - (d) / / Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
 - (e) / / An investment adviser in accordance with section 240.13d-1 (b) (1) (ii) (E).
 - (f) / An employee benefit plan or endowment fund in accordance with section 240.13d-1 (b) (1) (ii) (F).

Page 4 of 7

- (g) / / A parent holding company or control person in accordance with section 240.13d-1 (b) (1) (ii) (G).
- (h) / / A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i) / A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

(j) / Group, in accordance with section 240.13d-1(b)(1)(ii)(J).

ITEM 4. OWNERSHIP

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

Mr. Mangano's beneficial ownership includes (1) 3,750,000 shares of common stock issuable upon exercise of a warrant and 7,800,000 shares of common stock held by JO & Co; (2) 100,000 shares of common stock issuable upon exercise of stock options held by Mr. Mangano; (3) 30,000 shares of common stock held by Mr. Mangano; and (4) an aggregate of 2,250,001 shares of common stock and an aggregate of 1,124,999 shares of common stock issuable upon exercise of warrants held in various accounts of which Mr. Mangano is an advisor and/or trustee. Mr. Mangano has sole dispositive power over these shares. Mr. Mangano is the President of JO & Co.

JO & Co's beneficial ownership includes 3,750,000 shares of common stock issuable upon exercise of a warrant and 7,800,000 shares of common stock held by JO & Co.

Percent of class: Ross Mangano: 22.1% and JO & Co: 17.2%. The (b) foregoing percentages are calculated on the 63,208,798 shares of common stock reported to be outstanding by BioSante on its most recently filed quarterly report on Form 10-QSB for the quarter ended September 30, 2001.

- (c) Number of shares as to which Mr. Mangano has:
 - (i) Sole power to vote or to direct the vote

15,055,000 ______

(ii) Shared power to vote or to direct the vote

(iii) Sole power to dispose or to direct the disposition of

15,055,000

(iv) Shared power to dispose or to direct the disposition of

- (d) Number of shares as to which JO & Co has:
 - (i) Sole power to vote or to direct the vote

11,550,000

(ii) Shared power to vote or to direct the vote

Page 5 of 7

(iii) Sole power to dispose or to	
(iv) Shared power to dispose or	to direct the disposition of
ITEM 5. OWNERSHIP OF FIVE PERCENT OR L	
If this statement is being filed to hereof the reporting person has ceased five percent of the class of securities	
Not Applicable.	
ITEM 6. OWNERSHIP OF MORE THAN FIVE PE	RCENT ON BEHALF OF ANOTHER PERSON
Not Applicable.	
ITEM 7. IDENTIFICATION AND CLASSIFICAT THE SECURITY BEING REPORTED ON	
Not Applicable.	
ITEM 8. IDENTIFICATION AND CLASSIFICAT	ION OF MEMBERS OF THE GROUP
Not applicable.	
ITEM 9. NOTICE OF DISSOLUTION OF GROUP	
Not applicable.	
ITEM 10. CERTIFICATION	
Not applicable.	
SIGNA	
After reasonable inquiry and to the best that the information set forth in this	
	February 13, 2002
	Date
	/s/ ROSS MANGANO
	Ross Mangano
	JO & Co
	By: /s/ ROSS MANGANO

Ross Mangano Its: President

Page 6 of 7

EXHIBIT 1

Pursuant to Rule 13d-1(f)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required on Amendment No. 1 to Schedule 13G need be filed with respect to ownership by each of the undersigned of shares of common stock of BioSante Pharmaceuticals, Inc.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

Dated: February 13, 2002

/s/ ROSS MANGANO

Ross Mangano

JO & Co

By: /s/ ROSS MANGANO

Ross Mangano
Its: President

Page 7 of 7